Interpace Biosciences Swings to Q2 Profit as Thyroid Business Grows 9%

summarizeSummary

Interpace Biosciences returned to profitability in Q2 2026, with net income of $0.16 million versus a $0.64 million loss last year, as its thyroid testing business grew 9% and cost cuts took hold.

check_boxKey Events · Earnings and Guidance · IDXG

• Q2 Profitability Restored

  Net income of $0.16 million in Q2 2026, compared to a net loss of $0.64 million in Q2 2025, driven by a 9% increase in thyroid testing revenue and lower operating costs.

• Gross Margin Expansion

  Gross margin improved to 61.9% from 57.1% a year ago, reflecting lower variable costs and the absence of PancraGEN-related expenses.

• Cash Runway Extended

  Cash and cash equivalents stood at $2.7 million as of June 30, 2026, with management stating current resources are sufficient to meet anticipated cash requirements for the next twelve months.

• Reverse Split Vote Looms

  The earnings improvement comes ahead of a shareholder vote on a reverse stock split and authorized share increase, a key step toward a planned Nasdaq uplisting.

auto_awesomeAnalysis · IDXG · Industrial Applications And Services

A sharp turnaround to a net profit of $0.16 million in Q2 2026, from a $0.64 million loss a year ago, underscores the strength of Interpace Biosciences' core thyroid testing business, which grew 9%. Gross margins expanded to 61.9% from 57.1%, while operating expenses fell as restructuring costs from the discontinued PancraGEN test rolled off. With $2.7 million in cash and management projecting sufficient runway for the next twelve months, the company is stabilizing after the loss of its pancreatic cancer test reimbursement. These results arrive as shareholders are being asked to approve a reverse stock split and increase authorized shares—a vote critical for the company's Nasdaq uplisting ambitions.